SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report) SVP Michael A. Pisetsky sold 3,128 shares of the business's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total transaction of $44,229.92. Following the sale, the senior vice president now owns 244,878 shares of the company's stock, valued at approximately $3,462,574.92. This represents a 1.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
SI-BONE Price Performance
SIBN stock opened at $13.47 on Friday. The stock's 50 day moving average is $16.14 and its two-hundred day moving average is $14.71. SI-BONE, Inc. has a 52-week low of $11.70 and a 52-week high of $19.16. The company has a market capitalization of $571.84 million, a PE ratio of -14.64 and a beta of 1.02. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22.
SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.05. The firm had revenue of $49.00 million for the quarter, compared to the consensus estimate of $48.87 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. Analysts predict that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on SIBN shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price target on shares of SI-BONE in a research report on Tuesday, February 25th. Needham & Company LLC upped their target price on SI-BONE from $20.00 to $24.00 and gave the stock a "buy" rating in a research report on Tuesday, February 25th. Finally, Truist Financial reiterated a "buy" rating and set a $22.00 target price (up from $18.00) on shares of SI-BONE in a report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SI-BONE presently has a consensus rating of "Buy" and a consensus price target of $24.40.
View Our Latest Research Report on SI-BONE
Institutional Trading of SI-BONE
Hedge funds and other institutional investors have recently bought and sold shares of the company. Paradigm Capital Management Inc. NY lifted its holdings in SI-BONE by 5.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,386,031 shares of the company's stock worth $19,432,000 after buying an additional 69,831 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of SI-BONE by 8.3% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,666 shares of the company's stock valued at $1,439,000 after acquiring an additional 7,855 shares in the last quarter. Virtus Fund Advisers LLC bought a new position in SI-BONE during the fourth quarter worth $40,000. Virtus Investment Advisers Inc. acquired a new position in SI-BONE in the fourth quarter worth $196,000. Finally, Squarepoint Ops LLC bought a new stake in SI-BONE during the fourth quarter valued at $449,000. 98.11% of the stock is owned by institutional investors.
SI-BONE Company Profile
(
Get Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
